Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lemm, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lemm, G.

Neurology 2002;59:S28-S32
© 2002 American Academy of Neurology

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy

Georg Lemm, MD PhD

From the Bayer Corporation, Research Triangle Park, NC.

Address correspondence and reprint requests to Dr. Georg Lemm, Bayer Corporation, 4101 Research Commons, 79 TW Alexander Drive, Research Triangle Park, NC 27709.

The use of intravenous immune globulin (IVIg) has increased significantly in the past decade, benefiting a wide variety of immune diseases. Seven different formulations of IVIg are now licensed in the United States. Although all contain pooled IgG, there are differences in their production and composition that affect their efficacy, tolerability, and side-effect profile. Important variables include concentration, volume, osmolality, sodium, and sugar content. This article reviews what is known about the composition and properties of the various IVIg formulations that might affect the therapeutic outcome.




This article has been cited by other articles:


Home page
 BloodHome page
S. Jarius, P. Eichhorn, M. H. Albert, S. Wagenpfeil, M. Wick, B. H. Belohradsky, R. Hohlfeld, D. E. Jenne, and R. Voltz
Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNF{alpha}-dependent and Fc-receptor-independent way
Blood, May 15, 2007; 109(10): 4376 - 4382.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
S. Shah
Pharmacy considerations for the use of IGIV therapy
Am. J. Health Syst. Pharm., August 15, 2005; 62(16_Supplement_3): S5 - S11.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
D. A. Wetter, M. D. P. Davis, J. A. Yiannias, L. E. Gibson, M. V. Dahl, R. A. El-Azhary, A. J. Bruce, D. P. Lookingbill, I. Ahmed, A. L. Schroeter, et al.
Effectiveness of Intravenous Immunoglobulin Therapy for Skin Disease Other Than Toxic Epidermal Necrolysis: A Retrospective Review of Mayo Clinic Experience
Mayo Clin. Proc., January 1, 2005; 80(1): 41 - 47.
[Abstract] [PDF]

Home page
 BrainHome page
B. M. Lapointe, L. M. Herx, V. Gill, L. M. Metz, and P. Kubes
IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment
Brain, December 1, 2004; 127(12): 2649 - 2656.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.